Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they ...

Patients with narrowing of at least 50% in three major coronary arteries did equally well when treated with a minimally ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

Coronary artery bypass grafting is a more invasive procedure where surgeons use blood vessels from another part of the body ...

A Sunderland dad died weeks after a hospital error meant he went a week without vital medication after undergoing heart ...

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

Teleflex (TFX) announced that the preliminary results from its Ringer PBC IDE study were reported in a featured presentation at the CTO Plus ...

In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for CABG based on easy harvesting and relative greater patency over time, among ...